Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.
Genesys has generated more than 18 exits from 36 portfolio companies and has invested more than $200M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.
Our team has worked together for two decades of successful and continuous partnership.
Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.
We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.
We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.
Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.
Director of Finance and Operations
Ms. Williams is Director of Finance and Operations and joined Genesys Capital in 2002. Ms. Williams brings to Genesys a well-balanced range of skills. She has a proven track record of success in implementing a variety of major projects, and in working with senior stakeholders and key contacts. During her career with Genesys she has worked closely with the team to develop the operations and is responsible for finance and administration.
Ms. Williams graduated from the University of Guelph with an Honours Bachelor of Commerce and holds an MBA from Queen's University.
Co-founder, Managing Director
Mr. Lamb is co-Founder and Managing Director of Genesys Capital. With over 20 years experience in life sciences venture capital, he is one of Canada’s most experienced investors and company builders. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $300 million in venture capital funds, and has been involved in deploying over $200 million across 36 investments. He currently serves as Board Chair of Fusion Pharmaceuticals; and serves on the Boards of Flosonics Medical and the Centre for Probe Development and Commercialization at McMaster University. He has served on the Board of Affinium Pharmaceuticals (acquired Debiopharm), Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of Profound Medical Corp. (PROF) and DELEX Therapeutics Inc. when it was sold to YM BioSciences (now Gilead). Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.
Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences. Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with a Master of Science in Molecular Neurobiology and also holds an MBA from Queen’s University.
Mr. Stiff joined Genesys Capital in 2002 and became Partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in twelve early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include EBT Medical, Fairhaven Pharmaceuticals and Inversago Pharma. Past board affiliations include Allostera Pharma, gIcare Pharma, Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Jamie also volunteers as a board member for BioteCanada, and an advisor to both the Ontario Genomics Institute (OGI) and the Centre for Commercialization of Regenerative Medicine (CCRM) and as an associate with Creative Destruction Lab (CDL).
Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.
Dr. Farr joined Genesys Capital in 2020 as an Associate, bringing to the team eight years of experience at the bench in laboratory research and discovery. Before Genesys, Dr. Farr worked as a Business Development Officer in the Industry Partnerships & Commercialization office at the Hospital for Sick Children, where she identified commercial opportunities, managed industry partnerships, and handled the Research Institute’s intellectual property. She also led company creation efforts around a lead spin-off opportunity, including engagement of investors, pharma partners, and KOLs.
Dr. Farr holds a PhD from the Faculty of Medicine at the University of Toronto where she studied the effects of an anti-diabetic hormone on lipid and lipoprotein metabolism. She also has a Bachelor of Health Science (Honours) with a minor in Biochemistry from McMaster University.
Co-founder, Managing Director
Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $200 million across 36 investments. He currently serves on the Board of Directors of Adapsyn Bioscience, Functional Neuromodulation Ltd., IDbyDNA (observer), and Questat. From 2012-2015, he was a board observer with Invitae (NYSE: NVTA). From 2001 to 2013, he served on the board of Epocal, a Genesys portfolio company acquired by Alere (NYSE: ALR).
Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corporation. Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer’s disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s University.
Chief Financial Officer
Ms. Low joined Genesys Capital in 2007 in the role of Chief Financial Officer. Ms. Low has more than fifteen years of experience in finance and administration within the investment management industry. Ms. Low was also Chief Financial Officer of Covington Capital Corporation, a provider of venture capital investment funds where she was responsible for finance, operations, administration and compliance within the firm. Covington manages over $450 million in various retail venture capital funds and other investment vehicles.
Ms. Low is a Chartered Accountant and holds a Masters of Accounting degree from the University of Waterloo.
Paras came to the Genesys team from adMare Bioinnovations, where he was responsible for proactive identification of new opportunities, deal sourcing, financial valuations and company creation. Prior to his time at adMare, he served as a Management Consultant providing primary strategic insights to big pharma, and as a Venture Manager at the CDL.
Mr. Sharma has also held various scientific roles in early drug discovery group at Eisai Inc. and in clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at UPenn.
He holds a Bachelor of Technology from Amity University, a Master of Biotechnology from the University of Pennsylvania, and an MBA from Sauder School of Business in University of British Columbia.
Prior to joining Genesys in 2019, Elfrida worked as Business Planning Manager at Equitas Small Finance Bank Ltd., and at Axis Bank in administration, portfolio management and digital payments.
Elfrida holds a bachelor’s degree in Economics and a master’s degree in Finance from the University of Mumbai.
MONTREAL (CANADA), September 08, 2020 - Inversago Pharma Inc. today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité FTQ, and strong participation from existing investors Genesys Capital.
SAN FRANCISCO, March 17, 2020 – IDbyDNA Inc., a metagenomics technology company setting a standard for detection, identification and interpretation of microorganisms and their role in human health, today announced a global strategic partnership with Illumina, Inc. (Nasdaq: ILMN), to bring comprehensive next-generation sequencing (NGS) based workflows to the global microbiology market....
TORONTO, April 04, 2019 - Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control...
Apr. 2, 2019 - At US$105 million, this is one of the largest private financings in the history of the Canadian Life Sciences sector. The round was co-led by OrbiMed Advisors and Varian Medical Systems...
SAN FRANCISCO, Feb. 19, 2019 - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018...
BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019 - Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors...
MONTREAL (CANADA) – 25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases...
May 23, 2018 – Aptinyx, which is developing therapeutics for neurological disorders, filed on Wednesday with the SEC to raise up to $80 million in an initial public offering...